3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
14
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Small Cell Lung Carcinoma
9
Ovarian Neoplasms
8
Neuroblastoma
4
Retinoblastoma
3
Fallopian Tube Neoplasms
3
Sarcoma, Ewing
2
Lung Neoplasms
2
Ganglioneuroblastoma
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Recurrence
1
Pleuropulmonary blastoma
1
Peritoneal Neoplasms
1
Pediatric Brain Tumor
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Glioma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
venetoclax
124
Azacitidine
96
Cytarabine
71
fludarabine
44
Specimen Handling
38
Cyclophosphamide
38
Daunorubicin
27
Decitabine
26
Biopsy
25
Idarubicin
24
Granulocyte Colony-Stimulating Factor
21
gilteritinib
18
Injections
18
fludarabine phosphate
17
Whole-Body Irradiation
17
Melphalan
16
Busulfan
16
Stem Cell Transplantation
15
Mycophenolic Acid
15
ivosidenib
13
Cladribine
13
decitabine and cedazuridine drug combination
12
Gemtuzumab
12
Tacrolimus
11
CPX-351
11
X-Rays
10
Filgrastim
10
revumenib
9
enasidenib
9
Cyclosporine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Myeloid, Acute
×
Topotecan
×
Clear all
NCT05101551
2026-04-22
PARPAML
Stanford University
Phase 1
Recruiting
34 enrolled